AEs before and after emicizumab initiation for the complete cohort (N = 62)
| AE outcomes . | Before emicizumab initiation . | After emicizumab initiation . |
|---|---|---|
| Patients with AEs | 12 (19.4%) | 4 (6.5%) |
| AEs of special interest | ||
| AE related to IST∗ | 5 (8.1%) | 0 (0%) |
| Arterial thrombosis | 2 (3.2%) | 0 (0%) |
| NSTEMI/demand ischemia | 2 (3.2%) | 0 (0%) |
| TIA | 0 (%) | 1 (1.6%) |
| Venous thromboembolism | 0 (0%) | 1 (1.6%) |
| Infections owing to IST | 0 (0%) | 0 (0%) |
| Disseminated intravascular coagulation | 0 (0%) | 0 (0%) |
| Thrombotic microangiopathy | 0 (0%) | 0 (0%) |
| Other AEs | ||
| Infection (not related to IST) | 2 (3.2%) | 0 (0%) |
| Syncope | 1 (1.6%) | 0 (0%) |
| Weight loss | 1 (1.6%) | 0 (0%) |
| Arthralgia | 0 (0%) | 1 (1.6%) |
| Shortness of breath | 0 (0%) | 1 (1.6%) |
| AE outcomes . | Before emicizumab initiation . | After emicizumab initiation . |
|---|---|---|
| Patients with AEs | 12 (19.4%) | 4 (6.5%) |
| AEs of special interest | ||
| AE related to IST∗ | 5 (8.1%) | 0 (0%) |
| Arterial thrombosis | 2 (3.2%) | 0 (0%) |
| NSTEMI/demand ischemia | 2 (3.2%) | 0 (0%) |
| TIA | 0 (%) | 1 (1.6%) |
| Venous thromboembolism | 0 (0%) | 1 (1.6%) |
| Infections owing to IST | 0 (0%) | 0 (0%) |
| Disseminated intravascular coagulation | 0 (0%) | 0 (0%) |
| Thrombotic microangiopathy | 0 (0%) | 0 (0%) |
| Other AEs | ||
| Infection (not related to IST) | 2 (3.2%) | 0 (0%) |
| Syncope | 1 (1.6%) | 0 (0%) |
| Weight loss | 1 (1.6%) | 0 (0%) |
| Arthralgia | 0 (0%) | 1 (1.6%) |
| Shortness of breath | 0 (0%) | 1 (1.6%) |
AE, adverse event; NSTEMI, non–ST-elevation myocardial infarction.
AEs related to steroids included encephalopathy and hyperglycemia. AEs related to rituximab were infusion reactions; AEs related to daratumumab were hypersensitivity reactions. AEs related to bortezomib were infusion reactions.